Literature DB >> 26381030

Multispectral Imaging Approach to the Diagnosis of a CD20+ Cutaneous T-cell Lymphoproliferative Disorder: A Case Report.

Katrin A Salva1, Daniel Bennett, Jack Longley, Joan Guitart, Gary S Wood.   

Abstract

Expression of the pan B-cell marker CD20 by T-cell lymphoproliferative disorders is exceedingly rare. We present a 52-year-old man with a unilesional cutaneous CD20 T-cell lymphoproliferative disorder. Multispectral imaging analysis of CD3-CD20 double-stained lesional tissue sections allowed (1) the visualization of double-positive T lymphocytes in situ with sensitivity superior to that of conventional immunohistochemistry and (2) the quantitative assessment of marker coexpression. Here, 23% of CD3 signals in the patient's lesion were also CD20, whereas 38% of CD20 signals were also CD3. In contrast, both parameters were below 1% in the tonsil control. Overall, the percentage of double-positive cells in lesional skin was 35%, although only 0.4% of such cells were detected in the tonsil. This is the first demonstration of aberrant CD20 expression by skin-infiltrating T cells using multispectral imaging.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26381030      PMCID: PMC4576727          DOI: 10.1097/DAD.0000000000000323

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  16 in total

1.  Down-regulation of CD20 on B cells upon CD40 activation.

Authors:  Jennifer Anolik; R John Looney; Andrea Bottaro; Iñaki Sanz; Fay Young
Journal:  Eur J Immunol       Date:  2003-09       Impact factor: 5.532

2.  Circulating CD20dim T-lymphocytes increase with age: evidence for a memory cytotoxic phenotype.

Authors:  I Storie; G A Wilson; V Granger; D Barnett; J T Reilly
Journal:  Clin Lab Haematol       Date:  1995-12

Review 3.  Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS).

Authors:  H Bocquet; M Bagot; J C Roujeau
Journal:  Semin Cutan Med Surg       Date:  1996-12

4.  CD20 (pan-B cell antigen) expression on bone marrow-derived T cells.

Authors:  K M Algino; R W Thomason; D E King; M M Montiel; F E Craig
Journal:  Am J Clin Pathol       Date:  1996-07       Impact factor: 2.493

5.  Transient expression of CD20 antigen (pan B cell marker) in activated lymph node T cells.

Authors:  Y Murayama; R Mukai; T Sata; S Matsunaga; A Noguchi; Y Yoshikawa
Journal:  Microbiol Immunol       Date:  1996       Impact factor: 1.955

6.  CD20 positive T-cell lymphoma/leukemia: a rare entity with potential diagnostic pitfalls.

Authors:  Carl L Buckner; Lydia R Christiansen; Danyel Bourgeois; John J Lazarchick; John Lazarchick
Journal:  Ann Clin Lab Sci       Date:  2007       Impact factor: 1.256

7.  CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes.

Authors:  L E Hultin; M A Hausner; P M Hultin; J V Giorgi
Journal:  Cytometry       Date:  1993

8.  CD20-positive T-cell chronic lymphocytic leukaemia.

Authors:  A Takami; M Saito; S Nakao; H Asakura; T Nozue; Y Onoe; A Yachie; S Shiobara; T Matsuda
Journal:  Br J Haematol       Date:  1998-09       Impact factor: 6.998

9.  CD20 positive mycosis fungoides: a case report.

Authors:  Filiz Sen; Steven Kang; Joan Cangiarella; Hideko Kamino; Kenneth Hymes
Journal:  J Cutan Pathol       Date:  2008-02-04       Impact factor: 1.587

10.  Low level CD20 expression on T cell malignancies.

Authors:  M J Warzynski; D M Graham; R A Axtell; M H Zakem; R K Rotman
Journal:  Cytometry       Date:  1994-06-15
View more
  2 in total

1.  c-CBL E3 Ubiquitin Ligase Expression Increases Across the Spectrum of Benign and Malignant T-Cell Skin Diseases.

Authors:  Katrin A Salva; Margo J Reeder; Rita Lloyd; Gary S Wood
Journal:  Am J Dermatopathol       Date:  2017-10       Impact factor: 1.533

Review 2.  CD20+ T cells: an emerging T cell subset in human pathology.

Authors:  Adrian Y S Lee
Journal:  Inflamm Res       Date:  2022-08-11       Impact factor: 6.986

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.